drugset / Trial / NCT00049751

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

NCT00049751

Phase 3 Completed 3000 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).

Timeline

Start
2002-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody

Indications